EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segmentDevelopment of Eurobio Scientific proprietary product portfolioIncrease of international exposure Paris, 7th May 2024 – 06:30 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the signing on May 7th, 2024 of an agreement to acquire all rights to second generation gene expression test for breast cancer EndoPredict® from Myriad Genetics.

EUROBIO SCIENTIFIC签署协议，在肿瘤学领域获得乳腺癌ENDOPREDICT®扩展的基因表达测试EUROBIO SCIENTIFIC专有产品Portfolio的开发增加国际曝光巴黎，2024年5月7日下午6:30 EUROBIO SCIENTIFIC（FR0013240934，ALERS），（FR0013240934，ALERS，PEA-PME Qualified），一家领先的法国体外专业医学诊断和生命科学集团，宣布于2024年5月7日签署协议，从Myriad Genetics获得乳腺癌ENDOPREDICT®第二代基因表达测试的所有权利。

Consequently to this acquisition, Eurobio Scientific will grant Myriad Genetics a license for the manufacture, sale and distribution of the EndoPredict® Breast Cancer Prognosis Test for laboratory developed tests (LDT) that is mostly performed in the United States of America. In addition, Myriad Genetics will grant Eurobio Scientific a license for the manufacture, sale and distribution of Prolaris® Prostate Cancer Prognostic Kit Test.

因此，对于此次收购，Eurobio Scientific将授予Myriad Genetics制造、销售和分销EndoPredict®乳腺癌预后测试实验室开发测试（LDT）的许可证，该测试主要在美国进行。此外，Myriad Genetics将授予Eurobio Scientific生产、销售和分销Prolaris®前列腺癌预后试剂盒测试的许可证。

This acquisition and these agreements will allow Eurobio Scientific to complete its oncology portfolio with proprietary and distribution products. It will also strengthen its geographical footprint, mainly in Europe. Completion of this operation is expected in July 2024. EndoPredict® is a highly accurate second-generation multigene expression test for early-stage breast cancer.

此次收购和这些协议将使Eurobio Scientific能够通过专有和分销产品完成其肿瘤学投资组合。它还将加强其地理足迹，主要是在欧洲。预计该操作将于2024年7月完成。EndoPredict®是针对早期乳腺癌的高度准确的第二代多基因表达测试。

It provides crucial information to guide treatment decisions for patients with early-stage, hormone receptor-positive (RE-positive) and HER2-negative breast cancer. It predicts the risk of breast cancer recurrence (reappearance) up to 15 years after the initial diagnosis, helping clinicians determine whether a patient is at high or low risk for recurrence.

它为早期激素受体阳性（RE阳性）和HER2阴性乳腺癌患者的治疗决策提供了重要信息。它可以预测初次诊断后15年内乳腺癌复发（再次出现）的风险，帮助临床医生确定患者的复发风险是高还是低。